Mark J.  Enyedy net worth and biography

Mark Enyedy Biography and Net Worth

CEO of ImmunoGen
Mark J. Enyedy J.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining ImmunoGen, he served in various executive capacities at Shire PLC, a pharmaceutical company, from 2013 to 2016, including as Executive Vice President and Head of Corporate Development from 2014 to 2016, where he led Shire’s strategy, M&A and corporate planning functions and provided commercial oversight of Shire’s pre-Phase 3 portfolio. Prior to joining Shire, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Mr. Enyedy holds a JD from Harvard Law School and practiced law prior to joining Genzyme. Mr. Enyedy is also a director of Akebia Therapeutics, LogicBio Therapeutics, Inc., and The American Cancer Society of Eastern New England. Within the past five years, he also served as a director of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

What is Mark J. Enyedy's net worth?

The estimated net worth of Mark J. Enyedy is at least $13.79 million as of August 3rd, 2023. Mr. Enyedy owns 441,449 shares of ImmunoGen stock worth more than $13,786,452 as of November 24th. This net worth evaluation does not reflect any other investments that Mr. Enyedy may own. Additionally, Mr. Enyedy receives a salary of $1,280,000.00 as CEO at ImmunoGen. Learn More about Mark J. Enyedy's net worth.

How old is Mark J. Enyedy?

Mr. Enyedy is currently 60 years old. There are 4 older executives and no younger executives at ImmunoGen. Learn More on Mark J. Enyedy's age.

What is Mark J. Enyedy's salary?

As the CEO of ImmunoGen, Inc., Mr. Enyedy earns $1,280,000.00 per year. Learn More on Mark J. Enyedy's salary.

How do I contact Mark J. Enyedy?

The corporate mailing address for Mr. Enyedy and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at [email protected]. Learn More on Mark J. Enyedy's contact information.

Has Mark J. Enyedy been buying or selling shares of ImmunoGen?

Mark J. Enyedy has not been actively trading shares of ImmunoGen in the last ninety days. Most recently, Mark J. Enyedy sold 1,020,000 shares of the business's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $16.61, for a transaction totalling $16,942,200.00. Following the completion of the sale, the chief executive officer now directly owns 441,449 shares of the company's stock, valued at $7,332,467.89. Learn More on Mark J. Enyedy's trading history.

Who are ImmunoGen's active insiders?

ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (President, CEO & Director), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Are insiders buying or selling shares of ImmunoGen?

During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 338,452 shares worth more than $9,901,225.12. The most recent insider tranaction occured on January, 16th when SVP Theresa Wingrove sold 187,667 shares worth more than $5,562,449.88. Insiders at ImmunoGen own 5.1% of the company. Learn More about insider trades at ImmunoGen.

Information on this page was last updated on 1/16/2024.

Mark J. Enyedy Insider Trading History at ImmunoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/3/2023Sell1,020,000$16.61$16,942,200.00441,449View SEC Filing Icon  
2/24/2020Sell55,222$4.99$275,557.78433,776View SEC Filing Icon  
2/22/2019Sell51,070$5.60$285,992.00483,768View SEC Filing Icon  
2/21/2018Sell67,717$10.87$736,083.79532,383View SEC Filing Icon  
11/8/2016Buy25,000$1.83$45,750.00100,100View SEC Filing Icon  
See Full Table

Mark J. Enyedy Buying and Selling Activity at ImmunoGen

This chart shows Mark J Enyedy's buying and selling at ImmunoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ImmunoGen Company Overview

ImmunoGen logo
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
Read More

Today's Range

Now: $31.23
Low: $31.23
High: $31.23

50 Day Range

MA: $31.23
Low: $31.23
High: $31.23

2 Week Range

Now: $31.23
Low: $3.61
High: $31.25

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18